Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic results.

PLoS One · 2023 · PMC10355467 · PMID 37467213

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

There was an increasing trend in the baseline-adjusted LS means peak viral load with greater lumicitabine doses ( Table 4 ), with the 1.37 mg/kg group significantly lower than the placebo group (adjusted LS mean difference of −1.5, 95% CI: −2.73 to −0.31).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.